SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer, on October 3, 2013. The registrant is headquartered in Sydney, Australia, and files annual reports under Form 20-F. The filing serves to report a specific corporate governance event rather than periodic financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of a change in director's interest and does not contain financial statements or performance metrics.
Material Changes
The material change reported in this filing is the submission of a "Change of Director's Interest Notice" (Exhibit 99.1). No financial or operational changes compared to prior periods are detailed in this specific document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the director's interest change.
Key Facts for Investor Verification
- The filing discloses a change in a director's interest as of October 3, 2013.
- Matthew Lehman, Chief Executive Officer, signed the report on behalf of the registrant.
- Investors should review the attached Exhibit 99.1 for specific details regarding the nature and magnitude of the director's interest change.
- This filing does not contain financial performance data; refer to the most recent Form 20-F for financial metrics.